Active substanceInterferon alfa-2bInterferon alfa-2b
Similar drugsTo uncover
  • Altevir®
    solution for injections 
    FARMAPARK, LLC     Russia
  • Alpharone®
    lyophilizate nazal. 
    NPP FARMAKLON, LLC     Russia
  • Viferon®
    suppositories rect. 
    FERON, LLC     Russia
  • Grippferon®
    spray nazal. 
    FIRN M, ZAO     Russia
  • Grippferon®
    drops nazal. 
    FIRN M, ZAO     Russia
  • Interferal®
    aerosol locally 
  • Interferal®
    lyophilizate for injections 
  • Intron® A
    solution in / in PC 
  • Layfferon®
    lyophilizate w / m d / eye with / konyuk. 
    VECTOR-MEDICA, CJSC     Russia
  • Layfferon
    lyophilizate w / m d / eye with / konyuk. 
    VECTOR-MEDICA, CJSC     Russia
  • Layfferon®
    solution w / m d / eye with / konyuk. 
    VECTOR-MEDICA, CJSC     Russia
  • Realdiron®
    lyophilizate w / m PC 
  • Realdiron®
    lyophilizate w / m PC 
  • Reaferon-EU
    lyophilizate locally for injections 
    VECTOR-MEDICA, CJSC     Russia
  • Reaferon-EU-Lipint
    lyophilizatesuspension inwards 
    VECTOR-MEDICA, CJSC     Russia
  • Reaferon-EU-Lipint
    lyophilizatesuspension inwards 
    VECTOR-MEDICA, CJSC     Russia
  • Reaferon-LIPINT®
    capsules inwards 
    VECTOR-MEDICA, CJSC     Russia
  • Dosage form: & nbspnasal dosing spray
    Composition:

    1 ml contains:

    Active substance: interferon alfa-2b human recombinant not less than 10000 ME.

    1 dose contains:

    Active substance: interferon alfa-2b human recombinant not less than 500 ME.

    Excipients: disodium edetate dihydrate 0.5 mg, sodium chloride 4.1 mg, sodium hydrogen phosphate dodecahydrate 11.94 mg, potassium dihydrogen phosphate 4.54 mg, povidone-8 thousand 10 mg, macroline 4000 100 mg, water purified to 1 ml.

    Description:Transparent colorless or light yellow solution.
    Pharmacotherapeutic group:Cytokine - an antiviral, immunomodulating agent
    ATX: & nbsp

    L.03.A.B.05   Interferon alfa-2b

    Pharmacodynamics:The drug has an immunomodulatory, anti-inflammatory and antiviral effect.
    Pharmacokinetics:With intranasal application, the concentration of the active substance reached in the blood is well below the detection limit (the limit of determination of interferon alpha-2b -1-2 IU / ml) and has no clinical significance.
    Indications:
    Prevention and treatment of influenza and acute respiratory viral infections (ARVI) in children and adults.
    Contraindications:
    Individual intolerance to interferon preparations and components that make up the drug.
    Severe forms of allergic diseases.
    Pregnancy and lactation:Grippferon® is approved for use throughout the gestation period. Has no restrictions to use during lactation.
    Dosing and Administration:
    At the first sign of the disease, Grippferon® is used for 5 days:
    - at the age of 0 to 1 year, inject one dose (500 ME) into each nasal passage 5 times a day (single dose 1000 ME, daily dose 5000 ME);
    - at the age of 1 to 3 years, 2 doses are injected into each nasal passage 3-4 times a day (single dose 2000 ME, daily dose 6000-8000 ME);
    - at the age of 3 to 14 years, inject 2 doses into each nasal passage 4-5 times a day (single dose 2000 ME, daily dose 8000-10000 ME);
    - with 15 years and adults injected 3 doses in each nostril 5-6 times a day (single dose 3000 ME, daily dose 15000-18000 ME).
    In order to prevent ARVI and influenza:
    - when in contact with a patient and / or when supercooling, the drug is injected in a single age-related dosage 2 times a day once;
    - with a seasonal increase in the incidence of the drug is injected at an age-appropriate dosage once in the morning with an interval of 24-48 hours.
    - If necessary, preventive courses are repeated.
    To administer the drug, remove the protective cap, inject the spray device into the nasal passage and press the spray mechanism (1 dose -1 press) hard.Before the first application, press the spray mechanism several times until the spray cloud appears.
    Side effects:Not noted.
    Overdose:Data on drug overdose are absent.
    Interaction:The use of intranasal vasoconstrictor medications in conjunction with Grippferon® is not recommended, as this contributes to the additional drying of the nasal mucosa.
    Special instructions:The drug does not affect the ability to drive vehicles and mechanisms.
    Form release / dosage:Spray nasal dosed with 500 IU / dose.
    Packaging:1 bottle - 200 doses. For 10 ml in plastic bottles with a dispenser. On 1 bottle together with the instruction on application place in a pack from a cardboard.
    Storage conditions:At a temperature of 2 ° C to 8 ° C. Keep out of the reach of children.
    Shelf life:
    2 years. The opened vial should not be stored for more than 30 days.
    Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001503
    Date of registration:15.02.2012
    Expiration Date:15.02.2017
    The owner of the registration certificate:FIRN M, ZAO FIRN M, ZAO Russia
    Manufacturer: & nbsp
    FIRN M, ZAO Republic of Belarus
    Information update date: & nbsp10.05.2017
    Illustrated instructions
      Instructions
      Up